Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$4.07 – $6.85
100% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.5M | $47.5M | $199.5M | $243.5M | $293.6M | $328.2M | $371.3M | $449.7M |
| Cost of revenue | $2.3M | $20.5M | $117.8M | $128.1M | $155.5M | $175.5M | $196.9M | $299.1M |
| Gross profit | $10.2M | $26.9M | $81.7M | $115.4M | $138.1M | $152.7M | $174.4M | $150.6M |
| Gross margin | 81.6% | 56.7% | 40.9% | 47.4% | 47.0% | 46.5% | 47.0% | 33.5% |
| R&D | $2.0M | $3.9M | $11.7M | $12.7M | $14.8M | $17.5M | $23.3M | $29.0M |
| Operating income | −$17.6M | $14.0M | −$3.4M | −$5.3M | −$2.4M | −$2.9M | $7.4M | −$2.2M |
| EBITDA | −$3.9M | $27.4M | $28.6M | $42.6M | $25.3M | $40.9M | $64.4M | $54.3M |
| Net income | $24.1M | $14.5M | $31.8M | $15.7M | −$29.9M | −$16.8M | $4.3M | −$5.4M |
| Net margin | 192.6% | 30.6% | 15.9% | 6.4% | -10.2% | -5.1% | 1.2% | -1.2% |
| EPS (diluted) | 0.17 | 0.10 | 0.24 | 0.13 | -0.26 | -0.16 | 0.04 | -0.05 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $521M | $0.18 | $0.18–$0.19 | 1 |
| 2027 | $528M | $0.21 | $0.20–$0.22 | 1 |
| 2028 | $548M | $0.29 | $0.28–$0.30 | 1 |
| 2029 | $578M | $0.31 | $0.30–$0.32 | 1 |
Forward consensus · source: Financial Modeling Prep
KNIGHT THERAPEUTICS INC
No one on the platform currently holds KHTRF.
No tracked institution reports a position in KHTRF as of their last filing.
No one on the platform has traded KHTRF yet.
| $365M |
| — |
| CRLBFCresco Labs Inc. | $0.80 | -1.24% | $284M | — |
| HUMDFHua Medicine (Shanghai) Ltd. | $0.34 | +0.00% | $339M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 1.9× sales vs its 1.1× historical median P/S.
Fair value ≈ $4.20 · price $6.85 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.